20 years of lipid nanoparticles (SLN & NLC): Present state of development & industrial applications

Current Drug Discovery Technologies

Volumn 8, Issue 3, 2011, Pages 207-227

  Müller, Rainer H ^a   Shegokar, Ranjita ^a   Keck, Cornelia M ^a,b,c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES KAISERSLAUTERN   (Germany)

^c UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Cosmetics; Drug delivery; Lipid nanoparticles; Nanostructured lipid carriers; NLC; Nutraceuticals; Review; SLN; Solid lipid nanoparticles

Indexed keywords

CYCLOSPORIN A; EXCIPIENT; LIPOSOME; NANOCARRIER; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; NUTRACEUTICAL; OPTORAL; PEPTIDE DERIVATIVE; POLOXAMER; PROTEIN DERIVATIVE; SOLID LIPID NANOPARTICLE; TESTOSTERONE UNDECANOATE; TYLOXAPOL; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; COSMETIC INDUSTRY; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; GENE THERAPY; HUMAN; NANOPHARMACEUTICS; NANOTOXICOLOGY; NONHUMAN; PATENT; PRIORITY JOURNAL;

ANIMALS; COSMETICS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; EXCIPIENTS; GENE THERAPY; HISTORY, 20TH CENTURY; HUMANS; LIPIDS; NANOPARTICLES; PROTEINS;

EID: 79956102907     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/157016311796799062     Document Type: Article

References (196)

1. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. US-Patent 5250236;1993.
2. Lucks JS, Müller RH. Medication vehicles made of solid lipid particles (Solid Lipid Nanospheres - SLN). EP19920919477, WO/1993/005768;1993.
3. Gasco MR, Morel S. Lipospheres from Microemulsions. Farmaco 1990;45:1127-28. (Pubitemid 20371660)
4. Gasco MR, Morel S, Carpignano R. Optimization of the Incorporation of Deoxycorticosterone Acetate in Lipospheres. Eur J Pharm Biopharm 1992;38:7-10.
5. Lucks JS, Müller RH, König B. Solid lipid nanoparticles (SLN) - An alternative parenteral drug delivery system. Eur J Pharm Biopharm 1992;38:33.
6. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 1994;30:83-96. (Pubitemid 24173181)
7. Schwarz C, Mehnert W, Müller RH. Influence of production parameters of solid lipid nanoparticles (SLN) on the suitability for intravenous injection. Eur J Pharm Biopharm 1994;24 S: 40.
8. Müller RH, Mehnert W, Lucks JS, et al. Solid Lipid Nanoparticles (SLN) - an Alternative Colloidal Carrier System for Controlled Drug-Delivery. Eur J Pharm Biopharm 1995;41:62-69.
9. Westesen K, Wehler T. Investigation of the particle size distribution of a model intravenous emulsion. J Pharm Sci 1993;82:1237-44. (Pubitemid 23354144)
10. Bunjes H, Westesen K, Koch MJH. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 1996;129:159-73. (Pubitemid 26098737)
11. Siekmann B, Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur J Pharm Biopharm 1996;42:104-9. (Pubitemid 26173945)
12. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77. (Pubitemid 30326695)
13. Wissing SA, Müller RH. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 2003;254:65-8. (Pubitemid 36259812)
14. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72. (Pubitemid 38510473)
15. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie 2006;61:375-86. (Pubitemid 43724410)
16. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery-liposomes versus lipid nanoparticles. Int J Nanomedicine 2007;2:595-607.
17. Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2:289-300. (Pubitemid 350047774)
18. Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Patents on Drug Delivery Formulations 2008;2:120-35.
19. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84.
20. Gasco MR, Priano L, Zara GP. Chapter 10 - Solid lipid nanoparticles and microemulsions for drug delivery The CNS. Prog Brain Res 2009;180:181-92.
21. Brioschi A, Zenga F, Zara GP, et al. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol Res 2007;29:324-30. (Pubitemid 46802372)
22. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009;71:161-72.
23. Bunjes H, Drechsler M, Koch MH, Westesen K. Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. Pharm Res 2001;18:287-93. (Pubitemid 32595815)
24. Bunjes H, Koch MH, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci 2003;92:1509-20. (Pubitemid 36792763)
25. Jores K, Mehnert W, Drechsler M, et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 2004;95:217-27. (Pubitemid 38230037)
26. Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Del Rev 2007;59:379-402. (Pubitemid 47259221)
27. Bunjes H, Steiniger F, Richter W. Visualizing the structure of triglyceride nanoparticles in different crystal modifications. Langmuir 2007;23:4005-11. (Pubitemid 46581934)
28. Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm 2003;55:125-31. (Pubitemid 36120504)
29. Schubert MA, Müller-Goymann CC. Characterisation of surfacemodified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm 2005;61:77-86. (Pubitemid 41096691)
30. Attama AA, Schicke BC, Paepenmuller T, Muller-Goymann CC. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization. Eur J Pharm Biopharm 2007;67:48-57. (Pubitemid 46991314)
31. Schubert MA, Harms M, Müller-Goymann CC. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur J Pharm Sci 2006;27:226-36. (Pubitemid 41831258)
32. Nassimi M, Schleh C, Lauenstein HD, et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm; 75:107-16.
33. Müller RH, Mäder K, Lippacher A, Jenning V. Fest-flüssig (halbfeste) Lipidpartikel (Nano-Compartiment-Carrier-NCC) und Verfahren zur Herstellung hochkonzentrierter Lipidpartikel/Lipid particles based on matrix comprising solid and liquid lipid, useful in diagnostics and for controlled release of active agents, especially pharmaceuticals. DE19945203A1;1999.
34. Jenning V, Gohla S. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul 2001;18:149-58. (Pubitemid 32177833)
35. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007;59:478-90. (Pubitemid 47260710)
36. Rote Liste. Fachinformation. Aulendorf: Editio Cantor Verlag; 2003.
37. Müller RH, Olbrich C. Arzneistoffträger zur kontrollierten Wirkstoffaplikation hergestellt aus Lipidmatrix-Arzneistoff-Konjugaten. PCT/EP00/04112;2000.
38. Olbrich C, Geßner A, Kayser O, Müller RH. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug Diminazenediaceturate. J Drug Target 2002;10:387-96.
39. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52.
40. Bangham AD, Haydon DA. Ultrastructure of membranes: biomolecular organization. British Medical Bulletin 1968;24:124-6.
41. Diederichs JE, Müller RH. Liposome in Kosmetika und Arzneimitteln. Pharmazeutische Industrie 1994;56:267-275. (Pubitemid 24112129)
42. Müller BW. Suppositorien. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1986.
43. Kristl, J, Teskac K, Milek M, Mlinaric-Rascan I, Surface active stabilizer tyloxapol in colloidal dispersions exerts cytostatic effects and apoptotic dismissal of cells. Toxicol Appl Pharmacol 2008;232:218-25.
44. Acar S, Müller RH, Keck CM. Role of alpha-modification on physical stability of lipid nanoparticles. Annual Meeting of German Pharmaceutical Society (DPhG), Braunschweig 2010.
45. Acar S, Keck CM. Menthol loaded NLC: Reproducibillity and influence of production parameters on physicochemical properties. Int J Pharm in preparation.
46. Bargoni A, Cavalli R, Zara GP, et al. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II-tissue distribution. Pharmacol Res 2001;43:497-502. (Pubitemid 32578867)
47. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002;238:241-5. (Pubitemid 34457892)
48. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm 2002;241:341-4. (Pubitemid 34718035)
49. Bondi ML, Fontana G, Carlisi B, Giammona G. Preparation and characterization of solid lipid nanoparticles containing cloricromene. Drug Deliv 2003;10:245-50. (Pubitemid 37494138)
50. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 2003;56:189-96. (Pubitemid 37072102)
51. Ma P, Dong X, Swadley CL, et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 2009;5:151-61.
52. Sanjula B, Shah FM, Javed A, Alka A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 2009;17:249-56.
53. Shah KA, Joshi MD, Patravale VB. Biocompatible microemulsions for fabrication of glyceryl monostearate solid lipid nanoparticles (SLN) of tretinoin. J Biomed Nanotechnol 2009;5:396-400.
54. Sutthanut K, Lu X, Jay M, Sripanidkulchai B. Solid lipid nanoparticles for topical administration of Kaempferia parviflora extracts. J Biomed Nanotechnol 2009;5:224-32.
55. Kalam MA, Sultana Y, Ali A, et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target 2010;18:191-204.
56. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007;8:24.
57. Speiser P. Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung. EP 0167825;1990.
58. Müller RH, Dingler A, Schneppe T, Gohla S. Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTM). In: Wise D, ed. Handbook of Pharmaceutical Controlled Release Technology: CRC Press Inc.; 2000.
59. Muchow, M, P Maincent, R H Müller, et al., Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm 2010. 37:8-14.
60. Müller RH, Dingler A, Schneppe T, Gohla S. Large scale production of solid lipid nanoparticles (SLN") and nanosuspensions (DissoCubes"). In: Wise D, ed. Handbook of Pharmaceutical Controlled Release Technology. New York: Marcel Dekker Inc.; 2000:359-76.
61. Schwabe K, Keck CM, Industrial scaling up of nanostructured lipid carriers (NLC) production using reverse flow chamber technology, Annual Meeting of the German Pharmaceutical Society (DPhG), 1-3 Oktober, Jena/Germany, 2009.
62. FDA. 21 CFR Part 182, Substances Generally Recognized as Safe. 2010.
63. Maynard A. Small Wonder? Nanotechnology and cosmetics. 2020 Science 2008; online article.
64. Roth-Behrendt D. New EU cosmetics regulation: what's changing? Premium Beauty News 2009; online article.
65. Olbrich C, Müller RH. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm 1999;180:31-9. (Pubitemid 29131440)
66. Müller RH, Maapen S, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 1996;138:85-94. (Pubitemid 26241925)
67. Müller RH, Maaßen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996;4:161-70. (Pubitemid 26390298)
68. Müller RH, Mehnert W, Lucks JS, et al. Solid Lipid Nanoparticles (SLN) - An Alternative Colloidal Carrier System for Controlled Drug Delivery. Europ J Pharm Biopharm 1995;41:62-69.
69. Weyhers H, Ehlers S, Hahn H, Souto EB, Müller RH. Solid lipid nanoparticles (SLN)-effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie 2006;61:539-44. (Pubitemid 43989132)
70. Schöler N, Zimmermann E, Katzfey U, et al. Preserved solid lipid nanoparticles (SLN) at low concentrations do cause neither direct nor indirect cytotoxic effects in peritoneal macrophages. Int J Pharm 2000;196:235-9. (Pubitemid 30105751)
71. Scholer N, Hahn H, Muller RH, Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002;231:167-76. (Pubitemid 34033676)
72. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010;390:61-9.
73. Keck C, Hommoss A, Müller RH. Lipid nanoparticles for encapsulation of actives: dermal & oral formulations. Am Pharm Rev 2007;10:78-87.
74. Krzic M, Sentjurc M, Kristl J. Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo. J Control Release 2001;70:203-11. (Pubitemid 32144804)
75. Maia CS, Mehnert W, Schafer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 2000;196:165-7. (Pubitemid 30105735)
76. Sivaramakrishnan R, Nakamura C, Mehnert W, et al. Glucocorticoid entrapment into lipid carriers-characterisation by parelectric spectroscopy and influence on dermal uptake. J Control Release 2004;97:493-502. (Pubitemid 38802951)
77. Lombardi Borgia S, Regehly M, Sivaramakrishnan R, et al. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 2005;110:151-63. (Pubitemid 41713939)
78. Stecova J, Mehnert W, Blaschke T, et al. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res 2007;24:991-1000. (Pubitemid 46675401)
79. Schlupp P, Schmidts T, Siewert C, Mäder U, Mehnert W. Solid Lipid Nanoparticles (SLN) - an innovative carrier system for Sphingosine-1-phosphate (S1P). Euronanomedicine. Bled/Slovenia 2009.
80. Chopra I. The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J Antimicrob Chemother 2007;59:587-90. (Pubitemid 47073388)
81. Keck CM, Schwabe S, Rimpler C. Lipid Nanoparticles for the enhancement of the dermal action of solid particles. EP 08019 306.3;2008.
82. Patel M, Singh KK, Keck CM. Silver-nanolipid complex (sNLC): Antiinflammatory activity in murine mouse model of atopic dermatitis. 11th European Workshop on Particulate Systems (EWPS). Paris 2010.
83. Müller RH, Shegokar R, Singh KK. Positively charged nanostructured lipid carriers (NLC) for drug delivery by adhesion. 9th International Symposium on 'Advances in Technology and Business Potential of New Drug Delivery Systems' organized by Controlled Release Society-Indian Chapter. Mumbai 2009; P150.
84. Lange, K, Gysler A, Bader M, Kleuser B, Korting HC, Schäfer-Korting M, Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. Pharm Res 1997;14:1744-9. (Pubitemid 28062920)
85. Pople PV, Singh KK. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int J Pharm 2010;398(1-2):165-78.
86. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71-7. (Pubitemid 38670438)
87. Souto EB, Müller RM. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005;22:501-10. (Pubitemid 43123888)
88. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009;10:289-96.
89. Jain S, Jain S, Khare P, et al. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv 2010;17:443-51.
90. Sanna, V, E Gavini, M Cossu, et al. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. J Pharm Pharmacol, 2007. 59:1057-64. (Pubitemid 47265352)
91. Ballot S, Noiret N, Hindre F, et al. 99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution. Eur J Nucl Med Mol Imag 2006;33:602-7.
92. Charman WN. Lipids, lipophilic drugs and oral drug delivery-some emerging concepts. J Pharm Sci 2000;89:967-78.
93. Porter CJ, Charman WN. Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J Recept Signal Trans Res 2001;21:215-57. (Pubitemid 33091997)
94. Holm R, Porter CJ, Müllertz A, Kristensen HG, Charman WN. Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm Res 2002;19:1354-61.
95. Mainzer A, Müller E, Vonderscher J. Perorale Mikroemulsionsformulierung-Sandimmun Optoral/Neoral. In: Müller RH, Hildebrandt GE, eds. Pharmazeutische Technologie: Moderne Arzneiformen. 2 ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH; 1998:169-177.
96. Keck CM, Müller RH. Sandimmun Neoral - reason for the interindividual variations of bioavailability. Abstract - Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS). San Diego 2007.
97. Müller RH, Ravelli V, Runge SA. Pharmazeutische Ciclosporin- Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter Qualität und Stabilität sowie Verfahren zur Herstellung. DE 19819273A1;1998.
98. Muller RH, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 2006;317:82-9. (Pubitemid 43866342)
99. Penkler L, J., Muller, R, H., Runge, S., A., Ravelli, V. Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. US Patent 6, 551, 619;2003.
100. Cavalli R, Bargoni A, Podio V, et al. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003;92:1085-94. (Pubitemid 36523455)
101. Ponchel G, Irache J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 1998;34:191-219. (Pubitemid 28535112)
102. Jinno J, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006;111:56-64. (Pubitemid 43289995)
103. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004;12:65-70. (Pubitemid 38786914)
104. Reddy LH, Vivek K, Bakshi N, Murthy RS. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol 2006;11:167-77. (Pubitemid 43879940)
105. Yang L, Geng Y, Li H, et al. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Die Pharmazie 2009;64:86-89.
106. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 2006;114:53-9. (Pubitemid 44144503)
107. Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res 2009;20:115-123.
108. Li H, Zhao X, Ma Y, et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 2009;133:238-44.
109. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004;95:627-38. (Pubitemid 38344153)
110. Hanafy A, Spahn-Langguth H, Vergnault G, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev, 2007. 59:419-26 (Pubitemid 47260709)
111. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003;83:373-8. (Pubitemid 37464042)
112. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress, and challenges. J Antimicrob Chemo 2005;55:430-35. (Pubitemid 40542580)
113. He J, Hou SX, Feng JF, Cai BQ. Effect of particle size on oral absorption of silymarin-loaded solid lipid nanoparticles. Zhongguo Zhong Yao Za Zhi 2005;30:1651-3. (Pubitemid 44795730)
114. He J, Hou S, Lu W, Zhu L, Feng J. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Nanosci Nanotechnol 2007;3:195-202. (Pubitemid 351877170)
115. Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010;394:179-85.
116. Kasongo KW, Shegokar R, Müller RH, Walker RB. Formulation development and in-vitro characterization of didanosine loaded nanostructured lipid nanocarriers. International conference on "Advanced diagnostics and drug-delivery at the Nanoscale: state-ofthe-art and possible applications to orphan diseases 2009.
117. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly (butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995;41:44-48.
118. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995;674:171-4.
119. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Control Release 1997;49:81-87. (Pubitemid 27417903)
120. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly (butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003;20:409-16. (Pubitemid 36288370)
121. Kreuter J. Influence of the surface properties on nanoparticlemediated transport of drugs to the brain. J Nanosci Nanotechnol 2004;4:484-8. (Pubitemid 39387399)
122. Müller RH, Lück M, Kreuter J. Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation. EP 1023052B1;2003.
123. Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999;59:299-307. (Pubitemid 29238174)
124. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target 2006;14:632-45. (Pubitemid 44712359)
125. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005;107:215-28. (Pubitemid 41319672)
126. Doijad RC, Manvi FV, Godhwani DM, Joseph R, Deshmukh NV. Formulation and targeting efficiency of Cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci 2008;70:203-7. (Pubitemid 351920197)
127. Tian J, Pang X, Yu K, Liu L, Zhou J. Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin. Pharmazie 2008;63:593-7.
128. Reddy HL, Sharma RK, Chuttani K, Mishra AK, Murthy RS. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J Control Release 2005;105:185-98. (Pubitemid 40941985)
129. Zara GP, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002;10:327-35. (Pubitemid 34746314)
130. Liu J, Zhu J, Du Z, Qin B. Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles. Drug Dev Ind Pharm 2005;31:551-6. (Pubitemid 41285733)
131. Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur J Pharm Sci 2009;38:138-46.
132. Sharma, P, Ganta S, Denny WA, Garg S, Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: Chlorambucil. Int J Pharm 2009;367:187-94.
133. Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. J Nanosci Nanotechnol 2006;6:2991-5. (Pubitemid 44579973)
134. Wang Y, Deng Y, Mao S, et al. Characterization and body distribution of beta-elemene solid lipid nanoparticles (SLN). Drug Dev Ind Pharm 2005;31:769-78. (Pubitemid 41356193)
135. Wang W, Zhao X, Hu H, et al. Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability. Drug Deliv 2010;17:114-22.
136. Gupta, Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007;59:935-40. (Pubitemid 47051073)
137. Xiang QY, Wang MT, Chen F, et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 2007;30:519-25.
138. Shegokar R. Development and evaluation of novel drug delivery systems for an anti-HIV Drugs: PhD thesis, S. N. D. T. Women's University Mumbai; 2010.
139. Shegokar R, Singh KK, Müller RH. Targeted Stavudine Nanoparticles: Large scale production and long term stability. 11th European Workshop on Particulate Systems (EWPS). Paris 2010; p. 12.
140. Pang, X, F., Cui F, Tian J, Chen J, Zhou J, Zhou W, Preparation and characterization of magnetic solid lipid nanoparticles loaded with ibuprofen. Asian J Pharm Sci 2009;4:132-37.
141. Hernandez-Trejo N, Kayser O, Steckel H, Müller RH. Characterization of nebulized buparvaquone nanosuspensions-effect of nebulization technology. J Drug Target 2005;13:499-507. (Pubitemid 43347847)
142. Rudolph C, Schillinger U, Ortiz A, et al. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res 2004;21:1662-9. (Pubitemid 41184398)
143. Videira MA, Botelho MF, Santos AC, et al. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002;10:607-13. (Pubitemid 36124361)
144. Liu J, Gong T, Fu H, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008;356:333-44.
145. Videira MA, Gano L, Santos C, Neves M, Almeida AJ. Lymphatic uptake of lipid nanoparticles following endotracheal administration. J Microencapsul 2006;23:855-62. (Pubitemid 46332097)
146. Tabatt K. Pharmazeutisch-biotechnologische Anwendungen von Festen Lipidnanopartikeln (SLN): Vakzinadjuvantien und Gentransfervehikel/ Pharmaceutical-biotechnological applications of solid lipid nanoparticles (SLN): Vaccine adjuvants and gene transfer vehicles): Freie Universität Berlin; 2002.
147. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 2010:17:467-89.
148. Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008;364:76-86.
149. Gokce EH, Sandri G, Egrilmez S, et al. Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res 2009;34:996-1003.
150. Shen J, Sun M, Ping Q, Ying Z, Liu W. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology 2010;21:025101.
151. Basaran E, Demirel M, Sirmagul B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010;27:37-47.
152. Bondi ML, Azzolina A, Craparo EF, et al. Novel cationic solidlipid nanoparticles as non-viral vectors for gene delivery. J Drug Target 2007;15:295-301. (Pubitemid 47161496)
153. del Pozo-Rodriguez A, Delgado D, Solinis MA, et al. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int J Pharm 2009;385:157-62.
154. del Pozo-Rodriguez A, Delgado D, Solinis MA, Gascon AR, Pedraz JL. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int J Pharm 2007;339:261-8. (Pubitemid 46977611)
155. Olbrich C, Bakowsky U, Lehr CM, Müller RH, Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release 2001;77:345-55. (Pubitemid 33145485)
156. Battaglia L, Trotta M, Gallarate M, et al. Solid lipid nanoparticles formed by solvent-in-water emulsion-diffusion technique: development and influence on insulin stability. J Microencapsul 2007;24:660-72.
157. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine 2007;2:743-9.
158. Gallarate M, Trotta M, Battaglia L, Chirio D. Preparation of solid lipid nanoparticles from W/O/W emulsions: preliminary studies on insulin encapsulation. J Microencapsul 2009;26:394-402.
159. Yang R, Gao R, Li F, He H, Tang X. The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev Ind Pharm 2010;37:139-48.
160. Wang SL, Xie SY, Zhu LY, Wang FH, Zhou WZ. Effects of poly (lactic-co-glycolic acid) as a co-emulsifier on the preparation and hypoglycaemic activity of insulin-loaded solid lipid nanoparticles. IET Nanobiotechnol 2009;3:103-8.
161. Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm 2005;296:122-32. (Pubitemid 40693381)
162. del Pozo-Rodriguez A, Delgado D, Solinis MA, Gascon AR, Pedraz JL. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm 2008;360:177-83.
163. Müller RH, Maaßen S, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int J Pharm 1996;138:85-94. (Pubitemid 26241925)
164. Peira, E, Marzola P, Podio V, Aime S, Sbarbati A, Gasco MR, In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J Drug Target 2003;11:19-24. (Pubitemid 36527392)
165. Liu W, He Z, Liang J, et al. Preparation and characterization of novel fluorescent nanocomposite particles: CdSe/ZnS core-shell quantum dots loaded solid lipid nanoparticles. J Biomed Mat Res 2008;84:1018-25. (Pubitemid 351295012)
166. Cui, Z, Mumper RJ, The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur J Pharm Biopharm 2003;55:11-8. (Pubitemid 36120490)
167. Sznitowska M, Gajewska M, Janicki S, Radwanska A, Lukowski G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur J Pharm Biopharm 2001;52:159-63. (Pubitemid 32755894)
168. Yaziksiz-Iscan Y, Wissing SA, Müller RH, Hekimoglu S. Different production methods for solid lipid nanoparticles (SLNTM) containing the insect repellent deet. 4th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology ADRITELF/APV/APGI. Florence 2002.
169. Lai F, Wissing SA, Müller RH, Fadda AM. Artemisia arborescens L essential oil-loaded solid lipid nanoparticles for potential agricultural application: preparation and characterization. AAPS Pharm-SciTech 2006;7:E2.
170. Wellesley M. Global Nutraceutical Market Update. online article: http://www.naturalproductsinsider.com/news/2008/10/globalnutraceutical-market- update.aspxo2008; News, Market Data, Industry News.
171. Weiss J, Decker EA, McClements DJ, et al. Solid Lipid Nanoparticles as Delivery Systems for Bioactive Food Components. Food Biophysics 2008;3:146-54.
172. Patel MR, San Martin-Gonzalez MF. Characterization of ergocalciferol loaded solid lipid nanoparticles. IFT 10, Annual Meeting and Food Expo, Milan. 2010.
173. Hentschel A, Gramdorf S, Müller RH, Kurz T. Beta-caroteneloaded nanostructured lipid carriers. J Food Sci 2008;73:N1-6.
174. Junyaprasert VB, Teeranachaideekul V, Souto EB, Boonme P, Müller RH. Q10-loaded NLC versus nanoemulsions: stability, rheology and in vitro skin permeation. Int J Pharm 2009;377:207-14.
175. Müller RH, Mäder C, Wissing S. Mittel mit UV-Strahlung absorbierender und/oder reflektierender Wirkung zum Schutz vor gesundheitschädhlicher UV-Strahlung und Stärkung der natürlichen Hautbarriere. PCT/EP00/06534;2000.
176. de Vringer T. Topical preparation containing a suspension of solid lipid particles. EP 91200664 1992.
177. Perugini P, Bleve M, Pavanetto F. Development of solid lipid nanoparticles (SLN) for cosmetic application The International Nutraceutical, Cosmeceutical, "Functional Foods & Drinks" and "Health" Ingredients Trade Exhibition, Milan 2010.
178. Dingler A. Feste Lipid-Nanopartikelalskolloidale Wirkstoffträ gersysteme zur dermalen Applikation (Solid lipid nanoparticles as colloidal drug carriers for dermal application). PhD thesis, Freie Universtät Berlin; 1998.
179. Wissing S, Lippacher A, Müller R. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci 2001;52:313-24. (Pubitemid 33724124)
180. Wissing S, Müller R. The influence of the crystallinity of lipid nanoparticles on their occlusive properties. Int J Pharm 2002;242:377-9.
181. Wissing SA, Müller RH. Solid lipid nanoparticles (SLN)-a novel carrier for UV blockers. Pharmazie 2001;56:783-6. (Pubitemid 32971277)
182. Nikolic S, Keck CM, Anselmi C, Müller RH. NanoLipidCarriers (NLC) for safe and enhanced UV protection of skin. Eurobiotech. Krakow 2008.
183. Nikolic S, Keck CM, Müller RH. Lipid nanoparticles for synergistic skin photoprotection. 11th European Workshop on Particulate Systems (EWPS). Paris 2010.
184. Chanchal D, Saraf S. Novel approaches in herbal cosmetics. J Cos Derm 2008;7:89-95. (Pubitemid 351676526)
185. Averina ES, Seewald G, Müller RH, Radnaeva LD, Popov DV. Nanostructured lipid carriers (NLC) on the basis of Siberian pine (Pinus sibirica) seed oil. Die Pharmazie 2010;65:25-31.
186. Powers M. Innovata emerges as first suitor in acquisition play for SkyePharma. Nanobiotech News 2005;3:www.skyepharma.com.
187. Nili B. Proposal of Utilizing Solid Lipid Nanopellets, as Implantable Devices in Ophthalmic Disorders In: online article: www.nanodd.com/ocular- implants.pdf. Los Angeles: Nano Drug Delivery; 2004.
188. Kristl J, Teskac K, Milek M, Mlinaric-Rascan I. Surface active stabilizer tyloxapol in colloidal dispersions exerts cytostatic effects and apoptotic dismissal of cells. Toxicol Appl Pharmacol 2008;232:18-25.
189. Kristl J, Volk B, Ahlin P, et al. Interactions of solid lipid nanoparticles with model membranes and leukocytes studied by EPR. Int J Pharm 2003. 256: p. 133-40. (Pubitemid 36412146)
190. Ye J, Wang Q, Zhou X, Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 2008;352:273-9. (Pubitemid 351273921)
191. Attama AA, Reichl S, Muller-Goymann CC. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res 2009;34:698-705.
192. Olbrich C, Muller RH, Tabatt K, Kayser O, Schulze C, Schade R. Stable biocompatible adjuvants-a new type of adjuvant based on solid lipid nanoparticles: a study on cytotoxicity, compatibility and efficacy in chicken. Altern Lab Anim 2002;30:443-58.
193. Keck, CM, Müller RH, Silber-Lipid-Zwerge - Ein neues Therapiekonzept gegen Neurodermitis. Quantos 2010;1:6-11.
194. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004;113:151-70. (Pubitemid 39237077)
195. Muchow, M, Maincent P, Müller RH, Keck CM. Testosterone undecanoate - increase of oral bioavailability by nanostructured lipid carriers (NLC). Int J Pharm submitted.
196. Zur Muhlen, A, Schwarz C, Mehnert W, Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149-55. (Pubitemid 28167741)